|
UTP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.21990000112993E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.94020000030693E-07 |
| Normal-vs-Stage2 |
2.399100E-04 |
| Normal-vs-Stage3 |
1.73479999998616E-06 |
| Normal-vs-Stage4 |
8.50010000164048E-08 |
| Stage1-vs-Stage2 |
3.755600E-01 |
| Stage1-vs-Stage3 |
4.421600E-01 |
| Stage1-vs-Stage4 |
8.606100E-02 |
| Stage2-vs-Stage3 |
7.745400E-01 |
| Stage2-vs-Stage4 |
7.330600E-01 |
| Stage3-vs-Stage4 |
4.101600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63470000003052E-06 |
| Normal-vs-AfricanAmerican |
1.097800E-02 |
| Normal-vs-Asian |
1.253620E-02 |
| Caucasian-vs-AfricanAmerican |
4.747200E-01 |
| Caucasian-vs-Asian |
1.849240E-01 |
| AfricanAmerican-vs-Asian |
8.040600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.90119994694749E-09 |
| Normal-vs-Female |
9.36740000012648E-07 |
| Male-vs-Female |
1.303840E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63009999999408E-05 |
| Normal-vs-Age(41-60Yrs) |
4.05719999996279E-06 |
| Normal-vs-Age(61-80Yrs) |
4.87100000334806E-08 |
| Normal-vs-Age(81-100Yrs) |
1.933830E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.214400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.033700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.693000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.327600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.925400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.266400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.788800E-01 |
| Classical-VS-Follicular |
3.11389802831741E-11 |
| Classical-VS-Other |
2.607900E-02 |
| Classical-VS-Normal |
4.436900E-04 |
| Tall-VS-Follicular |
9.751900E-04 |
| Tall-VS-Other |
8.734500E-02 |
| Tall-VS-Normal |
9.442700E-04 |
| Follicular-VS-Other |
9.572400E-01 |
| Follicular-VS-Normal |
9.44688771653546E-13 |
| Other-VS-Normal |
4.762400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.71830000228468E-08 |
| Normal-vs-N1 |
1.00640000000318E-06 |
| N0-vs-N1 |
5.153200E-01 |
|
|
